TCGA showed that the mRNA of LILRB4 was significantly upregulated in breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD) and uterine corpus endometrial carcinoma (UCEC) compared to normal tissue (https://cistrome.shinyapps.io/timer/). Here, LILRB4 is linked to prostate adenocarcinoma.